Omicsveu
Private Company
Funding information not available
Overview
Founded in 2020, Omicsveu is a private, early-revenue stage company operating in the rapidly growing spatial biology market. It has developed a comprehensive technology platform centered on its NanoVIP all-in-one automated staining system, which is designed to standardize and streamline complex slide-based assays like multiplex immunofluorescence (Immunoveu) and in situ hybridization (RNAveu, miRNAveu). The company's product portfolio includes ready-to-use assay kits, antibodies, and probes, targeting academic, biopharma, and clinical research customers. Omicsveu's strategy focuses on providing an integrated workflow solution to improve reproducibility, throughput, and data quality in spatial transcriptomics and phenomics.
Technology Platform
Integrated spatial biology platform featuring the NanoVIP all-in-one automated staining system and a suite of reagent technologies (Immunoveu for multiplex protein detection, RNAveu for mRNA detection, miRNAveu for miRNA detection) for multi-omic analysis within tissue samples.
Opportunities
Risk Factors
Competitive Landscape
Omicsveu competes in the spatial biology market against major players like Akoya Biosciences, NanoString (now part of Bruker), and 10x Genomics, which offer integrated hardware and reagent systems. Its differentiation is based on the flexibility and automation of its NanoVIP system for adapting existing assays, potentially offering a more open and cost-effective alternative to proprietary ecosystems.